Published in Biologicals on July 01, 1991
Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J Clin Microbiol (1995) 1.84
Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol (2000) 1.39
A study of maternally derived measles antibody in infants born to naturally infected and vaccinated women. Epidemiol Infect (1996) 0.94
Immunosorbent assay based on recombinant hemagglutinin protein produced in a high-efficiency mammalian expression system for surveillance of measles immunity. J Clin Microbiol (1998) 0.90
Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques. Clin Vaccine Immunol (2008) 0.86
Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins. J Virol (2005) 0.85
Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children. Clin Diagn Lab Immunol (2004) 0.82
Measles immunity and response to revaccination among secondary school children in Cumbria. Epidemiol Infect (1996) 0.81
International reference preparation for anti-measles serum. Biologicals (1992) 0.75
Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature (1985) 6.01
Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J (1989) 4.12
New model for the secondary structure of the 5' non-coding RNA of poliovirus is supported by biochemical and genetic data that also show that RNA secondary structure is important in neurovirulence. J Mol Biol (1989) 4.09
The nucleotide sequence of poliovirus type 3 leon 12 a1b: comparison with poliovirus type 1. Nucleic Acids Res (1983) 4.06
Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b. Proc Natl Acad Sci U S A (1984) 3.98
The complete nucleotide sequence of a common cold virus: human rhinovirus 14. Nucleic Acids Res (1984) 3.85
Location and primary structure of a major antigenic site for poliovirus neutralization. Nature (1983) 3.64
Antigenic structure of polioviruses of serotypes 1, 2 and 3. J Gen Virol (1986) 3.50
The complete nucleotide sequence of coxsackievirus B4 and its comparison to other members of the Picornaviridae. J Gen Virol (1987) 3.01
An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature (1989) 3.01
Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol (1989) 2.89
Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3. Nature (1983) 2.51
Monoclonal antibodies which block cellular receptors of poliovirus. Virus Res (1984) 2.40
Antigen chimaeras of poliovirus as potential new vaccines. Nature (1988) 2.38
Role of horizontal genetic exchange in the antigenic variation of the class 1 outer membrane protein of Neisseria meningitidis. Mol Microbiol (1992) 2.27
Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472----U. Virology (1990) 2.03
Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J Virol (2000) 2.00
Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. J Gen Virol (1986) 1.99
Characterization of strains of type 3 poliovirus by oligonucleotide mapping. J Gen Virol (1982) 1.84
Characterisation of L cells expressing the human poliovirus receptor for the specific detection of polioviruses in vitro. J Virol Methods (1993) 1.82
Modulation of humoral response to a 12-amino-acid site on the poliovirus virion. J Virol (1986) 1.80
Synthesis of immunogenic, but non-infectious, poliovirus particles in insect cells by a baculovirus expression vector. J Gen Virol (1989) 1.77
Monoclonal antibodies specific for the Sabin vaccine strain of poliovirus 3. Lancet (1982) 1.76
Conservation in vivo of protease cleavage sites in antigenic sites of poliovirus. J Gen Virol (1987) 1.76
Decay-accelerating factor CD55 is identified as the receptor for echovirus 7 using CELICS, a rapid immuno-focal cloning method. EMBO J (1994) 1.76
Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3. J Gen Virol (1985) 1.72
Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis (1991) 1.72
Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res (1984) 1.71
The complete nucleotide sequence of coxsackievirus A21. J Gen Virol (1989) 1.70
The nucleotide sequence of human rhinovirus 1B: molecular relationships within the rhinovirus genus. J Gen Virol (1988) 1.67
Role for poliovirus protease 2A in cap independent translation. EMBO J (1994) 1.66
Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology (1993) 1.64
The complete nucleotide sequence of enterovirus type 70: relationships with other members of the picornaviridae. J Gen Virol (1990) 1.64
Intertypic genomic rearrangements of poliovirus strains in vaccinees. Virology (1988) 1.59
Molecular analysis of the serotyping antigens of Neisseria meningitidis. Infect Immun (1992) 1.51
Comparative biochemical studies of type 3 poliovirus. J Virol (1980) 1.49
Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J Virol (1989) 1.46
The 5' noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology (1991) 1.45
Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine. J Gen Virol (1995) 1.44
Poliovirus type 3: molecular cloning of the genome and nucleotide sequence of the region encoding the protease and polymerase proteins. Nucleic Acids Res (1983) 1.43
Construction of poliovirus intertypic recombinants by use of cDNA. J Virol (1986) 1.38
Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture. Virology (1992) 1.37
Absence of detectable measles virus genome sequence in blood of autistic children who have had their MMR vaccination during the routine childhood immunization schedule of UK. J Med Virol (2006) 1.35
Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding. J Virol (1995) 1.34
An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain. J Virol (1991) 1.31
New poliovirus vaccines: a molecular approach. Vaccine (1984) 1.28
Genetic and antigenic variation in type 3 polioviruses: characterization of strains by monoclonal antibodies and T1 oligonucleotide mapping. J Gen Virol (1982) 1.25
Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J Med Virol (1990) 1.22
Molecular cloning of the genomes of poliovirus type 3 strains by the cDNA: RNA hybrid method. Arch Virol (1984) 1.22
Inhibition of synthesis of influenza virus proteins: evidence of two host-cell-dependent events during multiplication. Virology (1975) 1.19
Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3. Virology (1985) 1.19
Serological responses in volunteers to inactivated trivalent subunit influenza vaccine: antibody reactivity with epidemic influenza A and B strains and evidence of a rapid immune response. J Med Virol (1991) 1.18
Nucleic acid sequence of the region of the genome encoding capsid protein VP1 of neurovirulent and attenuated type 3 polioviruses. Eur J Biochem (1983) 1.18
Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. J Virol (1995) 1.12
The nucleotide sequence of a type 3 poliovirus isolated during a recent outbreak of poliomyelitis in Finland. J Gen Virol (1986) 1.11
Role for beta2-microglobulin in echovirus infection of rhabdomyosarcoma cells. J Virol (1998) 1.11
Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies. J Gen Virol (1984) 1.09
The RNAs of defective-interfering influenza virus. Virology (1978) 1.09
Antigenic and molecular properties of type 3 poliovirus responsible for an outbreak of poliomyelitis in a vaccinated population. J Gen Virol (1986) 1.08
Sequence variation in the env gene of simian immunodeficiency virus recovered from immunized macaques is predominantly in the V1 region. J Gen Virol (1993) 1.07
An international collaborative study to establish the 2nd World Health Organization International Standard for hepatitis B virus DNA nucleic acid amplification technology-based assays. Vox Sang (2008) 1.07
Interaction of yellow fever virus French neurotropic vaccine strain with monkey brain: characterization of monkey brain membrane receptor escape variants. J Virol (2000) 1.06
The 5' noncoding region and virulence of poliovirus vaccine strains. Trends Microbiol (1994) 1.05
The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates. J Gen Virol (1993) 1.04
The Second International Standard for anti-poliovirus sera types 1, 2 and 3. Biologicals (1992) 1.03
Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. Virology (1999) 1.03
A hybridoma cell line secreting antibody to poliovirus type 3 D-antigen: detection in virus harvest of two D-antigen populations. J Gen Virol (1981) 0.99
Absence of detectable measles virus genome sequence in inflammatory bowel disease tissues and peripheral blood lymphocytes. J Med Virol (1998) 0.96
WHO collaborative study on the use of monoclonal antibodies for the intratypic differentiation of poliovirus strains. Bull World Health Organ (1986) 0.96
An approach to the control of disease transmission in pig-to-human xenotransplantation. Xenotransplantation (2000) 0.95
Genetic variation among strains of wild-type yellow fever virus from Senegal. J Gen Virol (1997) 0.94
RT-PCR based diagnosis and molecular characterisation of mumps viruses derived from clinical specimens collected during the 1996 mumps outbreak in Portugal. J Med Virol (1997) 0.94
Cellular and humoral immune responses to poliovirus in mice: a role for helper T cells in heterotypic immunity to poliovirus. J Gen Virol (1991) 0.94
Creation of an antigenic site in poliovirus type 1 by assembly of 14 S subunits. Virology (1990) 0.94
The influence of the host cell on standardisation of influenza vaccine potency. Dev Biol Stand (1999) 0.94
The preparation of specific immune sera against type 3 poliovirus D-antigen and C-antigen and the demonstration of two C-antigenic components in vaccine strain populations. J Gen Virol (1980) 0.93
Clinical safety issues of measles, mumps and rubella vaccines. Bull World Health Organ (2000) 0.93
Antigenic and genetic variation of the HN protein of mumps virus strains. J Gen Virol (1996) 0.93
Assay of humoral immunity to mumps virus. J Virol Methods (1999) 0.92
Clustering of mumps virus isolates by SH gene sequence only partially reflects geographical origin. Arch Virol (1997) 0.92
Collaborative study to establish a World Health Organization International genotype panel for parvovirus B19 DNA nucleic acid amplification technology (NAT)-based assays. Vox Sang (2011) 0.91
The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland. Virology (2000) 0.90
Antigenic sites on type 2 poliovirus. Virology (1993) 0.90
Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in the mumps Urabe vaccine strain. J Infect Dis (1998) 0.90
Selective inhibition of influenza virus protein synthesis by inhibitors of DNA function. Virology (1977) 0.90
Explanation of degree of correlation of sibling generation times in animal cells. Nature (1974) 0.90
Antigenic structure of poliovirus in inactivated vaccines. J Gen Virol (1993) 0.89
Immunochemical studies of polioviruses: identification of immunoreactive virus capsid polypeptides. J Gen Virol (1982) 0.89
Studies on the attenuation of the Sabin type 3 oral polio vaccine. J Virol Methods (1987) 0.88
An improved immunoblotting procedure for the detection of antibodies against HIV. J Virol Methods (1987) 0.87
Isolation of SV40 from the environment of a colony of cynomolgus monkeys naturally infected with the virus. Virology (2004) 0.87
Coding changes in the poliovirus protease 2A compensate for 5'NCR domain V disruptions in a cell-specific manner. Virology (2000) 0.87
Comparability of poliovirus neutralizing antibody tests. Biologicals (1992) 0.86
A collaborative study on DNA quantitation in biological products. Biologicals (1995) 0.86